Our findings suggest a hypothesis that topical ROCEN can potentially reduce pro-inflammatory cytokines such as TNF-α and IL-8, resulting in lipid homeostasis of the skin barrier in the lesion site and improvement of dermatitis symptoms. The gene discussed is CXCL8; the disease is skin disorder.